MKI67 and diffuse large B-cell lymphoma: A meta‐analysis,43 RCT (Ki67 threshold 75% in subgroup with IPI 2–3)44 and a couple of retrospective trials (different thresholds up to 85%)45, 46 demonstrated the significance of high Ki67 as a prognostic marker in rituximab treated DLBCL.